巨子生物：上半年权益股东应占利润达9.4亿元同比降20.5%

财中社08-18

8月18日，巨子生物（02367）发布2026年中期业绩，公司收入为29.18亿元，同比下降6.3%；毛利为23.18亿元，同比下降8.8%；税前利润为10.95亿元，同比下降24.2%；归属于公司权益股东利润为9.4亿元，同比下降20.5%；每股基本盈利为0.89元，同比下降21.9%。　　财务回顾显示，公司收入下降主要由于专业皮肤护理产品板块的销售结构调整，旨在提高长期经营质量。尽管整体...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2660182469?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-08-18 18:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2660182469","market":"sh","top_or_hot":-1,"title":"巨子生物：上半年权益股东应占利润达9.4亿元 同比降20.5%","media":"财中社","content":"<div>\n<p>8月18日，巨子生物（02367）发布2026年中期业绩，公司收入为29.18亿元，同比下降6.3%；毛利为23.18亿元，同比下降8.8%；税前利润为10.95亿元，同比下降24.2%；归属于公司权益股东利润为9.4亿元，同比下降20.5%；每股基本盈利为0.89元，同比下降21.9%。　　财务回顾显示，公司收入下降主要由于专业皮肤护理产品板块的销售结构调整，旨在提高长期经营质量。尽管整体...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202608183844670158.html\">网页链接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>巨子生物：上半年权益股东应占利润达9.4亿元 同比降20.5%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n巨子生物：上半年权益股东应占利润达9.4亿元 同比降20.5%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-18 18:17 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202608183844670158.html><strong>财中社</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>8月18日，巨子生物（02367）发布2026年中期业绩，公司收入为29.18亿元，同比下降6.3%；毛利为23.18亿元，同比下降8.8%；税前利润为10.95亿元，同比下降24.2%；归属于公司权益股东利润为9.4亿元，同比下降20.5%；每股基本盈利为0.89元，同比下降21.9%。　　财务回顾显示，公司收入下降主要由于专业皮肤护理产品板块的销售结构调整，旨在提高长期经营质量。尽管整体...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202608183844670158.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2488822045.USD","symbol_name":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","start_time":0,"source_url":"http://finance.eastmoney.com/a/202608183844670158.html","article_id":"2660182469","we_media_id":null,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608183844670158.html","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2660182469","pubTimestamp":1787048220,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"8月18日，巨子生物（02367）发布2026年中期业绩，公司收入为29.18亿元，同比下降6.3%；毛利为23.18亿元，同比下降8.8%；税前利润为10.95亿元，同比下降24.2%；归属于公司权益股东利润为9.4亿元，同比下降20.5%；每股基本盈利为0.89元，同比下降21.9%。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","02367":"巨子生物","BK1207":"个人用品","SG9999004311.SGD":"Nikko AM Shenton Emerging Enterprise Discovery Fund SGD"},"translate_title":"Giant Bio: Profit attributable to equity shareholders in the first half of the year reached 940 million yuan, down 20.5% year-on-year","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02367":1.5},"content_text":"8月18日，巨子生物（02367）发布2026年中期业绩，公司收入为29.18亿元，同比下降6.3%；毛利为23.18亿元，同比下降8.8%；税前利润为10.95亿元，同比下降24.2%；归属于公司权益股东利润为9.4亿元，同比下降20.5%；每股基本盈利为0.89元，同比下降21.9%。　　财务回顾显示，公司收入下降主要由于专业皮肤护理产品板块的销售结构调整，旨在提高长期经营质量。尽管整体销售收入下降，但公司通过加强品牌建设和自营渠道的拓展实现了自营端收入的同比增长。此外，报告期内其他收入显著增加，主要是由于利息收入的增长。　　在管理层讨论与分析中，公司提到持续加大研发投入，报告期内研发支出为4600万元，占收入的1.6%。公司已获批多项新产品，包括重组胶原蛋白和透明质酸钠复合溶液等，显示出在科技创新方面的进展。　　在业务分部方面，公司主要从事基于生物活性成分的美丽与健康产品的研发、制造及销售。整体收入主要来自于中国内地市场，未来公司将继续优化产品组合，推动业务回归稳定增长。（文章来源：财中社）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2660182469","isCrawlerRequest":true}

巨子生物：上半年权益股东应占利润达9.4亿元 同比降20.5%

精彩评论

巨子生物：上半年权益股东应占利润达9.4亿元同比降20.5%